van Der Ark Arno, von Straaten-Van De Kappelle Ineke, Hendriksen Coenraad F. M.
RIVM, NL-Bilthoven.
ALTEX. 1998;15(5):33-36.
We have developed the Pertussis Serological Potency Test (PSPT) as an alternative to potency testing of pertussis Whole Cell Vaccines (WCV) in the intracerebral Mouse Protection Test (MPT). The PSPT is based on the humoral antibody response against the whole range of B. pertussis surface-antigens per vaccine dose and correlates well with the MPT. WCV-induced-antibody responses against "protective" antigens; or the biological activitv of pertussis antibodies poorly correlated or did not correlate at all with mouse protection. Compared to the MPT the PSPT is more reproducible, reduces the animal distress and the number of animals in use. Moreover, the number of animals in use could be reduced even more by simplifying the multiple dose design to a single dose model and by combining in vitro assays for potency testing of tetanus, diphtheria and pertussis components in one animal model
我们已经开发出百日咳血清学效力试验(PSPT),以替代在脑内小鼠保护试验(MPT)中对百日咳全细胞疫苗(WCV)进行效力测试。PSPT基于每剂疫苗针对整个百日咳杆菌表面抗原范围的体液抗体反应,并且与MPT具有良好的相关性。WCV诱导的针对“保护性”抗原的抗体反应;或者百日咳抗体的生物学活性与小鼠保护的相关性很差或根本不相关。与MPT相比,PSPT具有更高的可重复性,减少了动物痛苦和所用动物的数量。此外,通过将多剂量设计简化为单剂量模型,并在一个动物模型中结合破伤风、白喉和百日咳成分效力测试的体外试验,所用动物的数量可以进一步减少。